Evaluation of cross-reacting anti-human antibodies in the euthymic hairless guinea pig model (HGP) suggests that the HGP may be a model for the study of proliferative skin disease.
Animal models have an important role in cutaneous research. The guinea pig has proven to be a useful model in a wide spectrum of these cutaneous studies; however, its usefulness is often compromised by the need for depilation. A euthymic hairless guinea pig (HGP) model avoids the problems associated with depilation. Morphologically, as in human skin, these animals have a multi-cell-layer epidermis. Proliferation kinetic studies, as well as documentation of the degree of immunologic cross-reactivity between available antibodies to human cutaneous antigens, could extend the usefulness of this animal model. We performed a battery of anti-human antibodies on formalin fixed tissue, to a variety of antigens present within the skin and on inflammatory cells. These included CD3, UCHL-1, OPD4, L-26, KP-1, Factor XIIIa, S-100 protein, cytokeratin (AE1, AE3 and CK1), CAM 5.2, vimentin, CD 34, Factor VIII, fibronectin, SM actin, collagen IV, laminin, Bcl-2, p53, Ki-67, and PCNA. Cross-reacting antibodies included: CD3, S-100 protein, cytokeratin (AE1, AE3 and CK1), vimentin, Factor VIII, SM actin, collagen IV, p53, Ki-67, and PCNA. Although this battery of antibodies is limited, the markedly increased staining of Ki-67 and PCNA within keratinocytes in the epidermis as compared to normal human skin reflects a high proliferative rate. In addition, positive staining for p53, Ki-67, and PCNA may be useful in studying effects on cell cycle kinetics and apoptosis.
Smith
K J
KJ
National Naval Medical Center, Department of Dermatology, Bethesda, Maryland, USA.
Graham
J S
JS
Skelton
H G
HG
O'Leary
T
T
Moeller
R B
RB
Okerberg
C V
CV
Hurst
C G
CG
D000199:Actins / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000032:analysis* / Q000276:immunology; D000918:Antibody Specificity; D017209:Apoptosis / Q000502:physiology; D017252:CD3 Complex / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D002455:Cell Division / Q000502:physiology; D003094:Collagen / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D003429:Cross Reactions; D004195:Disease Models, Animal; D005353:Fibronectins / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D015603:Keratinocytes / Q000737:chemistry / Q000473:pathology; D007633:Keratins / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D019394:Ki-67 Antigen / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D008297:Male; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D009418:S100 Proteins / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D012867:Skin / Q000737:chemistry* / Q000276:immunology / Q000473:pathology*; D012871:Skin Diseases / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D014746:Vimentin / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D014841:von Willebrand Factor / Q000032:analysis / Q000276:immunology / Q000378:metabolism
D000199:Actins; D000906:Antibodies; D017252:CD3 Complex; D005353:Fibronectins; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D009418:S100 Proteins; D016159:Tumor Suppressor Protein p53; D014746:Vimentin; D014841:von Willebrand Factor; D007633:Keratins; D003094:Collagen